Announcements Trials
Browse Landscape

Phase

Phase 2 94Phase 1 57Phase 1/2 32Phase 3 18Phase EARLY_PHASE1 3Phase NA 2Phase 4 2Phase 2/3 2

Status

Unknown 2Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Unresectable Non-small Cell Lung Cancer (NSCLC) 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Zoledronic Acid 28Saline Solution 26Metformin 25Dexamethasone 25Cyclophosphamide 23Cytarabine 22Bupivacaine 20Sodium Chloride 18Vincristine 17Methotrexate 17Letrozole 17Propofol 15Morphine 15Doxorubicin 15Cisplatin 15Prednisolone 14Docetaxel 14Dexmedetomidine 14Bevacizumab 14Oxycodone 13Imiquimod 13Fentanyl 13Capecitabine 13Rituximab 12Mercaptopurine 12Fluorouracil 12Granulocyte Colony-Stimulating Factor 11Everolimus 11Asparaginase 11Acetaminophen 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × durvalumab × Clear all
NCT04078152 2024-12-20

WAVE

AstraZeneca

Phase 4 Completed
163 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04416633 2024-11-08

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

AstraZeneca

Phase 4 Completed
100 enrolled 11 charts
Thoracic

Unresectable Non-small Cell Lung Cancer (NSCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡